Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Eptifibatide (Integrilin) vs Teduglutide (Gattex)
An educational, source-based comparison of Eptifibatide (Integrilin) and Teduglutide (Gattex) — how each peptide works, what it's researched for, and what to know before going deeper.
GP IIb/IIIa inhibitor cyclic peptide for ACS and PCI.
Cyclic heptapeptide derived from rattlesnake venom that reversibly blocks platelet glycoprotein IIb/IIIa receptors, preventing fibrinogen binding and platelet aggregation.
- Acute coronary syndromes
- PCI
- • FDA-approved.
- • Bleeding risk; renal adjustment required.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Eptifibatide (Integrilin) vs Teduglutide (Gattex) — Key differences
- Class: Eptifibatide (Integrilin) is classified as Antiplatelet · Cardiology, while Teduglutide (Gattex) is GLP-2 Analog · Gastrointestinal.
- Primary research focus: Eptifibatide (Integrilin) — acute coronary syndromes; Teduglutide (Gattex) — short bowel syndrome with intestinal failure.
- Tag: FDA-Approved · Cardiology vs FDA-Approved · GI.